Pancreas procedures

On October 27, 2022, the BfArM (Federal Institute for Drugs and Medical Devices) published the final version of the 2023 OPS procedure coding classification. The OPS, together with the ICD-10-GM (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification), forms the basis for the reimbursement systems in outpatient and inpatient care in Germany.

On October 17, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the decision, recommending the transfer to standard care for another completed project. The project relates to the improvement of the management of cancer patients.

In July 2022, the Dutch Organization for Health Research and Development (ZonMw) awarded 12 projects under the 2023 Open Round of the Efficiency Research program with a budget intended for funding research into clinical and cost-effectiveness of non-pharmaceutical care.

In January 2022, the Scottish Health Technology Group released a recommendation of the closed-loop systems and the artificial pancreas for type one diabetes mellitus. The limited use of closed-loop systems in routine clinical care makes it difficult to estimate device-related adverse event rates. No evidence was identified for artificial pancreas systems (multi-hormone closed-loop systems) available on the UK market.

In early July 2019, the network of European HTA agencies, EUnetHTA, published the report titled “Irreversible electroporation for the treatment of liver and pancreatic cancer”.

In mid-February 2019, the Swiss conference of cantonal healthcare directors (GDK/CDS) has published information about allocation of hospitals for highly complex visceral surgery in the fields of oesophageal, pancreatic and hepatic resections.